AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).